• 1
    Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 27185.
  • 2
    Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25: 25962.
  • 3
    Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229: 790800.
  • 4
    Mor E, Kaspa RT, Sheiner P, Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998; 129: 64353.
  • 5
    Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235: 46686.
  • 6
    Groupe d'Etude et de Traitment du Carcinome Hepatocellulaire. A comparison of Lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 125661.
  • 7
    Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with Lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29: 12934.
  • 8
    Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 116471.
  • 9
    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 17349.
  • 10
    Lautz HU, Selberg O, Korber J, Burger M, Muller MJ. Protein-calorie malnutrition in liver cirrhosis. Clin Invest 1992; 70: 47886.
  • 11
    Caregaro L, Alberino F, Amodio P, et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr 1996; 63: 6029.
  • 12
    O'Keefe SJ, Ogden J, Ramjee G, Rund J. Contribution of elevated protein turnover and anorexia to cachexia in patients with hepatocellular carcinoma. Cancer Res 1990; 50: 122630.
  • 13
    Kajiwara K, Okuno M, Kobayashi T, et al. Oral supplementation with branched-chain amino acids improves survival rate of rats with carbon tetrachloride-induced liver cirrhosis. Dig Dis Sci 1998; 43: 15729.
  • 14
    Marchesini G, Zoli M, Dondi C, Bianchi G, Cirulli M, Pisi E. Anticatabolic effect of branched-chain amino acid-enriched solutions in patients with liver cirrhosis. Hepatology 1982; 2: 4205.
  • 15
    Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331: 154752.
  • 16
    Meng WC, Leung KL, Ho RL, Leung TW, Lau WY. Prospective randomized controlled study on the effect of branched-chain amino acids in patients with liver resection for hepatocellular carcinoma. Aust NZ J Surg 1999; 69: 8115.
  • 17
    The San-In Group of Liver Surgery. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. Br J Surg 1997; 84: 152531.
  • 18
    Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: McLeodCM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press, 1949: 191205.
  • 19
    Poon RT, Ngan H, Lo CM, Liu CL, Fan ST, Wong J. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000; 73: 10914.
  • 20
    Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 1997; 84: 12559.
  • 21
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 5709.
  • 22
    Poon RT, Fan ST, Yu WC, Lam BK, Chan FY, Wong J. A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg 2001; 136: 6939.
  • 23
    Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994; 74: 1624.
  • 24
    Vetter D, Wenger JJ, Bergier JM, Doffoel M, Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology 1991; 13: 42733.
  • 25
    Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 91828.
  • 26
    Mondazzi L, Bottelli R, Brambilla G, et al. Transcatheter oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 1994; 19: 111523.
  • 27
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 42942.
  • 28
    O'Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003; 90: 32531.
  • 29
    Fan ST, Poon RT. Liver disease and parenteral nutrition. In: RombeauJL, RolandelliRH, eds. Clinical Nutrition: Parenteral Nutrition, 3rd edn. Philadelphia: W.B. Saunders, 2001: 392406.
  • 30
    Fabbri A, Magrini N, Bianchi G, Zoli M, Marchesini G. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. J Parenter Enteral Nutr 1996; 20: 15964.
  • 31
    Kato M, Miwa Y, Tajika M, Hiraoka T, Muto Y, Moriwaki H. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. Intern Med 1998; 37: 42934.
  • 32
    Watanabe A, Wakabayashi H, Kuwabara Y. Nutrient-induced thermogenesis and protein-sparing effect by rapid infusion of a branched chain-enriched amino acid solution to cirrhotic patients. J Med 1996; 27: 17682.
  • 33
    Yoshida T, Muto Y, Moriwaki H, Yamato M. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis. Gastroenterol Jpn 1989; 24: 6928.
  • 34
    Yamauchi M, Takeda K, Sakamoto K, Ohata M, Toda G. Effect of oral branched chain amino acid supplementation in the late evening on the nutritional state of patients with liver cirrhosis. Hepatol Res 2001; 21: 199204.
  • 35
    Yamashita Y, Torashima M, Oguni T, et al. Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation. Abdom Imaging 1993; 18: 3526.
  • 36
    Rogitti P, Peters JC, Tranberg KG, et al. Effects of amino acid infusions on liver regeneration after partial hepatectomy in the rat. J Parenter Enteral Nutr 1986; 10: 1720.
  • 37
    Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124: 1792801.
  • 38
    Sugiyama K, Yu L, Nagasue N. Direct effect of branched-chain amino acids on the growth and metabolism of cultured human hepatocellular cells. Nutr Cancer 1998; 31: 628.
  • 39
    Saito Y, Saito H, Nakamura M, et al. Effect of the molar ratio of branched-chain to aromatic amino acids on growth and albumin mRNA expression of human liver cancer cell lines in a serum-free medium. Nutr Cancer 2001; 39: 12631.